These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 20599590

  • 1. A substance P mediated pathway contributes to 6-hydroxydopamine induced cell death.
    Thornton E, Tran TT, Vink R.
    Neurosci Lett; 2010 Aug 30; 481(1):64-7. PubMed ID: 20599590
    [Abstract] [Full Text] [Related]

  • 2. Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway.
    Chu JM, Chen LW, Chan YS, Yung KK.
    Neuropharmacology; 2011 Dec 30; 61(8):1389-98. PubMed ID: 21907219
    [Abstract] [Full Text] [Related]

  • 3. Intrapallidal injection of 6-hydroxydopamine induced changes in dopamine innervation and neuronal activity of globus pallidus.
    Bouali-Benazzouz R, Tai CH, Chetrit J, Benazzouz A.
    Neuroscience; 2009 Dec 01; 164(2):588-96. PubMed ID: 19628021
    [Abstract] [Full Text] [Related]

  • 4. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
    Ganser C, Papazoglou A, Just L, Nikkhah G.
    Exp Cell Res; 2010 Mar 10; 316(5):737-46. PubMed ID: 20060824
    [Abstract] [Full Text] [Related]

  • 5. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
    Gomes MZ, Raisman-Vozari R, Del Bel EA.
    Brain Res; 2008 Apr 08; 1203():160-9. PubMed ID: 18313645
    [Abstract] [Full Text] [Related]

  • 6. Striatal glutamate release evoked in vivo by NMDA is dependent upon ongoing neuronal activity in the substantia nigra, endogenous striatal substance P and dopamine.
    Marti M, Manzalini M, Fantin M, Bianchi C, Della Corte L, Morari M.
    J Neurochem; 2005 Apr 08; 93(1):195-205. PubMed ID: 15773919
    [Abstract] [Full Text] [Related]

  • 7. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T, Shingo T, Muraoka K, Kameda M, Agari T, Wen Ji Y, Hayase H, Hamada H, Borlongan CV, Date I.
    Brain Res; 2005 Aug 16; 1053(1-2):10-8. PubMed ID: 16045899
    [Abstract] [Full Text] [Related]

  • 8. Effect of acupuncture on 6-hydroxydopamine-induced nigrostratal dopaminergic neuronal cell death in rats.
    Kim YK, Lim HH, Song YK, Lee HH, Lim S, Han SM, Kim CJ.
    Neurosci Lett; 2005 Aug 16; 384(1-2):133-8. PubMed ID: 15893426
    [Abstract] [Full Text] [Related]

  • 9. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats.
    Smith AD, Kozlowski DA, Bohn MC, Zigmond MJ.
    Exp Neurol; 2005 Jun 16; 193(2):420-6. PubMed ID: 15869944
    [Abstract] [Full Text] [Related]

  • 10. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU, Oertel WH, Hartmann A.
    Exp Neurol; 2008 Mar 16; 210(1):182-93. PubMed ID: 18053987
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons.
    Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R, Labandeira-Garcia JL.
    Neurobiol Aging; 2007 Apr 16; 28(4):555-67. PubMed ID: 16621167
    [Abstract] [Full Text] [Related]

  • 12. Polychlorinated biphenyl-induced neurotoxicity in organotypic cocultures of developing rat ventral mesencephalon and striatum.
    Lyng GD, Snyder-Keller A, Seegal RF.
    Toxicol Sci; 2007 May 16; 97(1):128-39. PubMed ID: 17324953
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease.
    Yasuhara T, Shingo T, Kobayashi K, Takeuchi A, Yano A, Muraoka K, Matsui T, Miyoshi Y, Hamada H, Date I.
    Eur J Neurosci; 2004 Mar 16; 19(6):1494-504. PubMed ID: 15066146
    [Abstract] [Full Text] [Related]

  • 15. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM, Faull RL, Connor B.
    Neuroscience; 2008 Feb 19; 151(4):1142-53. PubMed ID: 18201835
    [Abstract] [Full Text] [Related]

  • 16. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxydopamine lesions.
    Mohapel P, Frielingsdorf H, Häggblad J, Zachrisson O, Brundin P.
    Neuroscience; 2005 Feb 19; 132(3):767-76. PubMed ID: 15837137
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS, Tang LL, Zheng SS, Zhan RY, Zhou YQ, Goudreau J, Kaufman D, Chen AF.
    Brain Res Mol Brain Res; 2005 Mar 24; 134(1):155-61. PubMed ID: 15790539
    [Abstract] [Full Text] [Related]

  • 19. Postnatal administration of D1 dopamine agonist reverses neonatal dopaminergic lesion-induced changes in striatal enkephalin and substance P systems.
    Sivam SP, Cox J.
    Brain Res; 2006 Feb 16; 1073-1074():159-63. PubMed ID: 16455064
    [Abstract] [Full Text] [Related]

  • 20. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
    Carta AR, Tronci E, Pinna A, Morelli M.
    Eur J Neurosci; 2005 Mar 16; 21(5):1196-204. PubMed ID: 15813929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.